In the last few days I had been working on an update of my January piece. It was both a fundamental and a comprehensive analysis of the colorectal cancer screening market and of the two front-running companies in the field of innovative, non-invasive early detection: Berlin based Epigenomics AG (OTC:EPGNF) and Madison based Exact Sciences Inc. (EXAS). (The Seeking Alpha article is itself a summary of a paper that can be downloaded from my homepage)
The bottom line was unambiguous:
"EpiProColon is not a perfect test, but it brings to the party all you need to revolutionize the CRC early detection market:
1) performance is good enough and at least matches the performance of FIT,
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: